Background This study examined the effects of growth hormone (GH) treatment on growth and metabolic parameters, gross motor function, and musculoskeletal complications in children with cerebral palsy. Methods This retrospective single-center study included children who received GH treatment for over 1 year. Data on growth-related variables, metabolic indicators, and disease-specific factors were collected. Statistical analyses examined associations between GH treatment duration and outcomes, with pre- and post-treatment comparisons. Results Twenty-two patients were enrolled in this study. GH treatment significantly improved height and weight Z-scores, along with insulin-like growth factor-1 Z-scores, regardless of GH deficiency or ambulatory status. Metabolic changes significantly included an increased bone age-to-chronological age ratio, decreased aspartate aminotransferase levels, and elevated uric acid levels. The gross motor function did not decline, and there was no significant worsening of hip subluxation or scoliosis. Conclusion GH treatment led to significant improvements in growth and metabolic-related parameters without adverse effects on gross motor function or musculoskeletal complications. These findings suggest that GH treatment may be a safe and effective treatment option for children with cerebral palsy, providing potential benefits without increasing the risk of orthopedic complications. Impact <UnorderedList Mark="Bullet"> <ItemContent> This study is the first to assess the long-term effects of GH treatment in children with CP. </ItemContent> <ItemContent> GH treatment improved height, weight, and insulin-like growth factor-1 Z-scores. </ItemContent> <ItemContent> Gross motor function did not decline during treatment, and no significant worsening of hip subluxation or scoliosis detected. </ItemContent> <ItemContent> There is a lack of longitudinal studies on the long-term effects of growth hormone administration in children with CP. </ItemContent> <ItemContent> It is anticipated that this study will lay the groundwork for large-scale multicenter prospective research. </ItemContent> </UnorderedList>

Growth hormone treatment in cerebral palsy: long-term impact on growth, outcomes, and complications

期刊论文
发表日期：

2025年9月30日

查看全文

Juntaek Hong,
Sujin Kim,
Junghwan Suh,
Dong-wook Rha

摘要

Background

This study examined the effects of growth hormone (GH) treatment on growth and metabolic parameters, gross motor function, and musculoskeletal complications in children with cerebral palsy.

Methods

This retrospective single-center study included children who received GH treatment for over 1 year. Data on growth-related variables, metabolic indicators, and disease-specific factors were collected. Statistical analyses examined associations between GH treatment duration and outcomes, with pre- and post-treatment comparisons.

Results

Twenty-two patients were enrolled in this study. GH treatment significantly improved height and weight Z-scores, along with insulin-like growth factor-1 Z-scores, regardless of GH deficiency or ambulatory status. Metabolic changes significantly included an increased bone age-to-chronological age ratio, decreased aspartate aminotransferase levels, and elevated uric acid levels. The gross motor function did not decline, and there was no significant worsening of hip subluxation or scoliosis.

Conclusion

GH treatment led to significant improvements in growth and metabolic-related parameters without adverse effects on gross motor function or musculoskeletal complications. These findings suggest that GH treatment may be a safe and effective treatment option for children with cerebral palsy, providing potential benefits without increasing the risk of orthopedic complications.

Impact

This study is the first to assess the long-term effects of GH treatment in children with CP.

GH treatment improved height, weight, and insulin-like growth factor-1 Z-scores.

Gross motor function did not decline during treatment, and no significant worsening of hip subluxation or scoliosis detected.

There is a lack of longitudinal studies on the long-term effects of growth hormone administration in children with CP.

It is anticipated that this study will lay the groundwork for large-scale multicenter prospective research.